LEO Pharma Gets EU Go-Ahead For Psoriasis Latecomer Brodalumab
The Danish speciality dermatology company LEO Pharma has achieved a key plank in its plans to provide products for the range of psoriasis patients with an EU go-ahead for brodalumab.
You may also be interested in...
Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.
Two European companies with portfolios in skin conditions have taken their first collaborative steps, researching non-painful skin sampling.
Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.